Alzheimer’s drug lecanemab granted full approval by FDA, Mayo Clinic expert weighs in

The Food and Drug Administration (FDA) granted traditional approval of a disease-modifying treatment that could potentially give some patients with Alzheimer’s disease something they haven’t had before: a medication that may slow the decline of memory and thinking.

A monoclonal antibody, lecanemab, shows promise in removing amyloid plaques from the brain, according to phase 3 trial results. Amyloid plaques are one of the defining features of Alzheimer’s disease, according to Dr. Ronald Petersen, a neurologist and director of the Mayo Clinic Alzheimer’s Disease Research Center.
____________________________________________
FOR THE PUBLIC: More health and medical news on the Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/

FOR THE MEDIA ONLY: Register at https://newsnetwork.mayoclinic.org/re… to access clean and nat sound versions of this video on the Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/

Mayo Clinic https://mayocl.in/3tNMAdF Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Like Mayo Clinic on Facebook: https://www.facebook.com/ Follow Mayo Clinic on Twitter: https://twitter.com/MayoClinic